Company: ANTX
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0000950170-25-107301
Chunk: 10

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 6
Chunk 10
---
(a)Exhibits. 

The exhibits listed below are filed as part of this Quarterly Report on Form 10-Q.

     Incorporated by Reference

     ExhibitNumber
      
     Description
      
     Form
      
     File No.
      
     Exhibit
      
     Filing Date

     3.1
      
     Amended and Restated Certificate of Incorporation.
      
     8-K
      
     001-41331
      
     3.1
      
     June 24, 2024

     3.2
      
     Amended and Restated Bylaws.
      
     S-1
      
     333-263295
      
     3.4
      
     March 4, 2022

     3.3
      
     Certificate of Designations of Series A Junior Participating Preferred Stock of AN2 Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on August 15, 2024.
      
     8-K
      
     001-41331
      
     3.1
      
     August 19, 2024

     4.1
      
     Rights Agreement, dated as of August 15, 2024, between AN2 Therapeutics, Inc. and Equiniti Trust Company, LLC, which includes Form of Certificate of Designations of Series A Junior Participating Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C.
      
     8-K
      
     001-41331
      
     4.1
      
     August 19, 2024

     4.2
      
     Form of Pre-Funded Warrant
      
     8-K
      
     001-41331
      
     4.1
      
     June 20, 2025

     10.1*#
      
     Amended and Restated AN2 Therapeutics, Inc. 2022 Non-Employee Director Compensation Policy

     31.1*
      
     Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of